Enavatuzumab

DB33653InvestigationalProtein Based Therapies

Enavatuzumab: Overview.

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 12A
Curator reviewed
Code names: PDL-192

Resolves to

Compound

Targets

What you can answer from here — as of August 28, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Enavatuzumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.